Skip to main content
. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832

Figure 2.

Figure 2

Kaplan-Meier plot of progression-free survival (PFS) in the GANNET53 Phase I trial. All 10 patients included experienced disease progression (no censored cases).